## Abstract ## BACKGROUND Ninety percent of children with diffuse, intrinsic brainstem tumors will die within 18 months of diagnosis. Radiotherapy is of transient benefit to these children, and a potential way to improve its efficacy is to add radiosensitizers. Carboplatin is antineoplastic and ra
Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas
โ Scribed by Roger J. Packer; Mark Krailo; Minesh Mehta; Katherine Warren; Jeffrey Allen; Regina Jakacki; Judith G. Villablanca; Akiko Chiba; Gregory Reaman
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 107 KB
- Volume
- 104
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Background: Diffuse pontine gliomas remain one of the most lethal of pediatric malignancies despite the use of increasingly intensive therapies. we delivered intensive chemotherapy during and following 70.2 gy of hyperfractionated radiation therapy in an attempt to improve survival. ## Procedur
## BACKGROUND. Brainstem gliomas often respond to radiotherapy but long term disease control is exceptional. The concomitant administration of a chemotherapy agent with radiosensitizing properties such as carboplatin may increase the efficacy of radiotherapy.
## BACKGROUND. Prognosis for the majority of children with brain stem gliomas is dismal. In previous studies, recombinant beta-interferon (@IF) has been shown to be effective for children with recurrent brain stem gliomas and may also act synergistically with radiotherapy (RT). ## METHODS. Thir